All News
Telemedicine Outcomes in RA Care
A new short‐term follow‐up study has shown no significant difference in outcomes and quality measures in patients with RA who were managed by telemedicine (compared to usual in-person care).
Read Article
RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Read Article
High Burnout Rates Among Rheumatologists
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
Read Article
Biologic Use for Arthritis Linked With Depression and Anxiety
In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.
Read Article
Outpatient Visits Return to Pre-COVID Rates
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
Read Article
TNF Inhibitors or non-TNF Biologics - First Best Choice?
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar
Read Article
Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.
Read Article
COVID Transmission from Young to Old
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
Read Article
Tofacitinib and Thromboembolic Risk
Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m
Read Article
Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Read Article
Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Read Article
RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Biologics Beneficial in Eosinophilic Vasculitis
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Read Article
Sustained Remission Off Therapy Unlikely in GPA
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
Read Article
IL-1 Inhibition Alters Arthroplasty Rates
A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.
Read Article
Fractures from Delays in Denosumab Reinfusions
Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t
Read Article
Systemic Steroids Reduce Mortality in COVID-19
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
